Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - procaine benzylpenicillin, quantity: 1.5 g - injection, suspension - excipient ingredients: sodium citrate dihydrate; water for injections; polysorbate 80 - indications as at 18 february 2002: treatment of moderately severe infections due to penicillin sensitive organisms. therapy should be guided by bacteriological studies, including sensitivity tests and also by clinical response. infections which usually respond to adequate dosage are: group a streptococcal infections including upper respiratory tract infections, skin and skin structure infections and scarlet fever; pneumococcal infections of the respiratory tract; susceptible staphylococcal infections, most gonococcal infections, syphilis, fusospirochaetosis (vincent's gingivitis and pharyngitis). cilicaine syringe 1.5 must be administered by the intramuscular route only (see section 4.2 dose and method of administration).

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - procaine benzylpenicillin monohydrate 435 mg/ml;  ;  ; procaine benzylpenicillin monohydrate 435 mg/ml - suspension for injection - 435 mg/ml - active: procaine benzylpenicillin monohydrate 435 mg/ml     excipient: phenylmercuric acetate polysorbate 80 sodium citrate dihydrate water for injection active: procaine benzylpenicillin monohydrate 435 mg/ml excipient: polysorbate 80 sodium citrate dihydrate water for injection

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - chloroprocaine hydrochloride (unii: lt7z1yw11h) (chloroprocaine - unii:5yvb0pot2h) - chloroprocaine hydrochloride 20 mg in 1 ml - chloroprocaine hydrochloride injection 2% and 3%, in single dose vials, without methylparaben preservative, without edta, is indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks. chloroprocaine hydrochloride injection is not to be used for subarachnoid administration. chloroprocaine hydrochloride is contraindicated in patients hypersensitive (allergic) to drugs of the paba ester group. lumbar and caudal epidural anesthesia should be used with extreme caution in persons with the following conditions: existing neurological disease, spinal deformities, septicemia, and severe hypertension.

United States - English - NLM (National Library of Medicine)

international medication systems, limited - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride 100 mg in 1 ml - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete he

United States - English - NLM (National Library of Medicine)

hospira, inc. - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride 100 mg in 1 ml - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete he

United States - English - NLM (National Library of Medicine)

nexus pharmaceuticals llc - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride 1000 mg - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete hear

United States - English - NLM (National Library of Medicine)

mckesson corporation - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride 100 mg in 1 ml - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete h

Ireland - English - HPRA (Health Products Regulatory Authority)

agepha pharma s.r.o. - oxybuprocaine hydrochloride - eye drops, solution - oxybuprocaine

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios syva, s.a.u - benzylpenicillin procaine monohydrate - suspension for injection - 300 milligram(s)/millilitre - procaine benzylpenicillin

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and box